Adverum Biotechnologies, Inc.
Adverum Biotechnologies, Inc. (ADVM) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · ADVM · as of Sep 30, 2025
Ownership Breakdown
50
Institutional Holders
▼ 7 vs Q2
$61.46M
Total Inst. Value
▲ $32.42M vs Q2
22.08M
Shares Outstanding
freeFloat 62.34%
13.57M
13F Shares Held
▲ 63,488 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
ADVM largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BML CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 3.06M | 14.55% | 14.55% | $13.85B | Nov 10, 2025 | — held |
PRINCIPIA WEALTH ADVISORY, LLC biological products, (no diagnostic substances) | 2.08M | 9.89% | 9.89% | $9.41B | Feb 10, 2026 | ▲ 48.8K |
FRAZIER LIFE SCIENCES MANAGEMENT, L.P. biological products, (no diagnostic substances) | 2.08M | 9.89% | 9.89% | $9.41B | Nov 14, 2025 | ▲ 1.01M |
TCG CROSSOVER MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.67M | 7.94% | 7.94% | $7.56B | Nov 17, 2025 | ▼ 128.3K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 872.0K | 4.15% | 4.15% | $3.95B | Nov 7, 2025 | ▼ 11.9K |
5AM VENTURE MANAGEMENT, LLC biological products, (no diagnostic substances) | 541.7K | 2.58% | 2.58% | $2.45B | Nov 14, 2025 | — held |
GOLDMAN SACHS GROUP INC biological products, (no diagnostic substances) | 402.6K | 1.92% | 1.92% | $1.82B | Nov 14, 2025 | ▼ 94.7K |
RENAISSANCE TECHNOLOGIES LLC biological products, (no diagnostic substances) | 363.5K | 1.73% | 1.73% | $1.65B | Nov 13, 2025 | ▼ 207.2K |
PALE FIRE CAPITAL SE biological products, (no diagnostic substances) | 363.3K | 1.73% | 1.73% | $1.65B | Nov 13, 2025 | ▲ 4.6K |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 324.4K | 1.54% | 1.54% | $1.47B | Nov 14, 2025 | ▼ 17.9K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
10
Increased
+1.19M shares5
New Positions
first time holders22
Decreased
−864.7K shares0
Sold Out
fully exitedNet shares change (top 50)
+329.6K
+1.19M / −864.7K
Net new holders
-7
5 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
ADVM insider trading · insider activity
Source: SEC Form 4
10
Buy transactions
102
Sell transactions
0.10
Buy/Sell ratio
$9M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Fischer Laurent CEO, PRESIDENT AND DIRECTOR | Dec 9, 2025 | Award | 500,000 | — | — | 522.7K | Form 4 ↗ |
Fischer Laurent CEO, PRESIDENT AND DIRECTOR | Dec 9, 2025 | U-Tender | 25,000 | $3.56 | $89.0K | 0 | Form 4 ↗ |
Fischer Laurent CEO, PRESIDENT AND DIRECTOR | Dec 9, 2025 | D-Return | 200,000 | $7.15 | $1.43M | 0 | Form 4 ↗ |
Fischer Laurent CEO, PRESIDENT AND DIRECTOR | Dec 9, 2025 | D-Return | 93,000 | $7.50 | $697.5K | 0 | Form 4 ↗ |
Fischer Laurent CEO, PRESIDENT AND DIRECTOR | Dec 9, 2025 | U-Tender | 351,513 | $3.56 | $1.25M | 0 | Form 4 ↗ |
Fischer Laurent CEO, PRESIDENT AND DIRECTOR | Dec 9, 2025 | U-Tender | 522,666 | $3.56 | $1.86M | 0 | Form 4 ↗ |
Fischer Laurent CEO, PRESIDENT AND DIRECTOR | Dec 9, 2025 | D-Return | 110,420 | $10.14 | $1.12M | 0 | Form 4 ↗ |
Soparkar Peter CHIEF OPERATING OFFICER | Dec 9, 2025 | Award | 150,000 | — | — | 157.3K | Form 4 ↗ |
Soparkar Peter CHIEF OPERATING OFFICER | Dec 9, 2025 | D-Return | 39,476 | $10.14 | $400.3K | 0 | Form 4 ↗ |
Soparkar Peter CHIEF OPERATING OFFICER | Dec 9, 2025 | D-Return | 78,750 | $4.20 | $330.8K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Adverum Biotechnologies, Inc. (ADVM) is primarily owned by institutional investors, who hold approximately 61.5% of total shares outstanding. Company insiders own approximately 37.66%, while retail and public investors account for the remaining 0.89%.
The largest institutional shareholder of Adverum Biotechnologies, Inc. is BML CAPITAL MANAGEMENT, LLC, holding approximately 3.06 million shares — equal to 14.55% of outstanding shares — as of September 30, 2025.
A total of 50 institutional investors currently hold ADVM stock, with a combined institutional value of approximately $61,458,813 as of the most recent 13F filing period.
Frequently asked questions
ADVM ownershipAdverum Biotechnologies, Inc. (ADVM) is primarily owned by institutional investors, who hold approximately 61.5% of shares. The largest shareholder is BML CAPITAL MANAGEMENT, LLC with a 14.55% stake. Company insiders hold 37.66%. Data sourced from SEC Form 13F as of September 30, 2025.